591 related articles for article (PubMed ID: 30270065)
21. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
22. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
[TBL] [Abstract][Full Text] [Related]
23. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.
Saltijeral A; Pérez de Isla L; Alonso R; Muñiz O; Díaz-Díaz JL; Fuentes F; Mata N; de Andrés R; Díaz-Soto G; Pastor J; Pinilla JM; Zambón D; Pinto X; Badimón L; Mata P;
Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):444-450. PubMed ID: 27913073
[TBL] [Abstract][Full Text] [Related]
24. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
[TBL] [Abstract][Full Text] [Related]
25. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
[TBL] [Abstract][Full Text] [Related]
26. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
27. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
[TBL] [Abstract][Full Text] [Related]
28. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
[TBL] [Abstract][Full Text] [Related]
29. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
31. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
[TBL] [Abstract][Full Text] [Related]
33. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
Alonso R; Arroyo-Olivares R; Muñiz-Grijalvo O; Díaz-Díaz JL; Muñoz-Torrero JS; Romero MJ; de Andrés R; Zambón D; Mañas MD; Fuentes-Jiménez F; Aguado R; Alvarez-Baños P; Arrieta F; Gonzalez-Bustos P; Cepeda J; Martin-Ordiales M; Mosquera D; Michan A; de Isla LP; Argueso R; Mata P
Eur J Prev Cardiol; 2023 Mar; 30(4):320-328. PubMed ID: 36416136
[TBL] [Abstract][Full Text] [Related]
34. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
[TBL] [Abstract][Full Text] [Related]
35. PCSK9 inhibitors in clinical practice: Delivering on the promise?
Stoekenbroek RM; Hartgers ML; Rutte R; de Wijer DD; Stroes ESG; Hovingh GK
Atherosclerosis; 2018 Mar; 270():205-210. PubMed ID: 29254691
[TBL] [Abstract][Full Text] [Related]
36. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
Kayikcioglu M; Tokgozoglu L; Dogan V; Ceyhan C; Tuncez A; Kutlu M; Onrat E; Alici G; Akbulut M; Celik A; Yesilbursa D; Sahin T; Sonmez A; Ozdogan O; Temizhan A; Kilic S; Bayram F; Sabuncu T; Coskun FY; Ildizli M; Durakoglugil E; Kirilmaz B; Yilmaz MB; Yigit Z; Yildirim AB; Gedikli O; Topcu S; Oğuz A; Demir M; Yenerçağ M; Yıldırır A; Demircan S; Yilmaz M; Kaynar LG; Aktan M; Durmus RB; Gokce C; Ozcebe Oİ; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O; Can LH
Atherosclerosis; 2018 Oct; 277():341-346. PubMed ID: 30270069
[TBL] [Abstract][Full Text] [Related]
37. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
[TBL] [Abstract][Full Text] [Related]
38. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
[TBL] [Abstract][Full Text] [Related]
39. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
